Cataratas

Aspergillus niger and A. oryzae are established industrial sources of beta-galactosidase (lactase) used to manage lactose intolerance. Multiple randomized placebo-controlled trials demonstrate that A. niger-derived lactase significantly reduces breath hydrogen excretion and gastrointestinal symptoms in lactase-deficient adults. A randomized double-blind crossover study confirmed A. oryzae acid lactase combined with yogurt bacteria synergistically improved lactose digestion.

B. coagulans efficiently metabolizes lactose through a combination of extracellular enzymatic activity and intracellular metabolism, preventing undigested lactose from reaching the large intestine where it would cause fermentation and GI symptoms. This mechanism is documented in patent literature and referenced mechanistic reviews.

Multiple Bifidobacterium species produce β-galactosidase and have been shown in randomized trials and a 2023 systematic review/meta-analysis to improve lactose digestion and reduce LI symptoms including abdominal pain, diarrhea, bloating, and flatulence. Five separate studies reported favorable outcomes from Bifidobacterium supplementation in managing lactose intolerance. Effects are strain- and dose-dependent.

Bifidobacterium animalis subsp. lactis Bi-07 has been evaluated in two crossover RCTs (Booster Alpha and Booster Omega) demonstrating superiority over placebo in reducing breath hydrogen concentration in lactose-intolerant individuals. Bi-07 showed higher β-galactosidase activity than other tested strains including Lactobacillus acidophilus NCFM and standard yogurt cultures.

Bifidobacterium bifidum has been shown in clinical studies to reduce abdominal pain and overall symptom scores in lactose-intolerant adults. A 2023 meta-analysis (Journal of Dairy Science) identified it as one of the effective monostrain probiotics for abdominal pain and total LI symptoms. It produces β-galactosidase that aids colonic lactose metabolism.

Bifidobacterium breve Yakult, administered in combination with Lactobacillus casei Shirota, demonstrated significant and sustained improvement (lasting 3 months post-therapy) in symptom severity scores and hydrogen gas production in a clinical study of lactose-intolerant patients. Multiple studies confirm its β-galactosidase production relevant to lactose metabolism.

Bifidobacterium lactis (Bi-07 strain) has the highest documented β-galactosidase activity among tested probiotic strains and was superior to placebo in two crossover RCTs for lactose intolerance. Multiple studies and a meta-analysis confirm its efficacy for reducing breath hydrogen and LI symptoms. It is one of the most-evidenced probiotic strains for this condition.

Bifidobacterium longum has been tested in multiple RCTs for lactose intolerance, including a randomized double-blind crossover study (n=23) where B. longum BB536 combined with Lactobacillus rhamnosus HN001 and vitamin B6 alleviated persistent GI symptoms in LI subjects on a lactose-free diet. B. longum also increases fecal β-galactosidase activity. A capsule trial (Jaagura et al., 2022) showed improved symptom scores and microbiota modulation.

Coconut milk is inherently lactose-free, making it a well-documented and clinically recognized dairy alternative for individuals with lactose intolerance. Its use avoids the gastrointestinal symptoms (bloating, gas, diarrhea) associated with lactose malabsorption, and it is nutritionally viable as a dairy substitute in cooking and beverage contexts.

Galactooligosaccharides (GOS) are prebiotics that have been studied specifically for lactose intolerance in multiple clinical trials. A 377-subject randomized, double-blind, multisite placebo-controlled trial found that 30-day GOS supplementation significantly reduced LI symptoms and shifted the fecal microbiome toward lactose-fermenting bacteria. GOS exerts its benefit by selectively enriching Bifidobacterium and other colonic lactose-metabolizing species.

Galactosidase (β-galactosidase) is the enzymatic class underlying lactase activity and is the direct treatment target in lactose intolerance management. Supplemental β-galactosidase has been studied in multiple controlled trials in children and adults, showing reductions in lactose breath hydrogen and symptom scores. It is equivalent in function to exogenous lactase supplementation.

Lactase (β-galactosidase) directly hydrolyzes lactose into glucose and galactose in the small intestine, the core enzymatic deficit in lactose intolerance. Multiple randomized controlled trials demonstrate that oral lactase supplementation significantly reduces breath hydrogen excretion and gastrointestinal symptoms. A double-blind crossover RCT (n=47) found a 55% reduction in cumulative hydrogen breath levels versus placebo. EFSA recognizes a health claim for lactase supplementation with dairy consumption.

Lactobacillus acidophilus is one of the most widely studied probiotics for lactose intolerance, with three RCTs included in a 2023 meta-analysis and consistent evidence of β-galactosidase production. A double-blind crossover study (n=38) of L. acidophilus DDS-1 found statistically significant improvements in diarrhea, abdominal cramps, vomiting, and overall symptom scores versus placebo.

Lactobacillus bulgaricus (L. delbrueckii subsp. bulgaricus) is a primary yogurt starter culture with well-documented β-galactosidase activity that improves lactose digestion. EFSA's health claim for live yogurt cultures improving lactose digestion was supported by 14 human intervention studies. A 2023 meta-analysis confirms it as one of the most effective probiotic strains for lactose intolerance, with higher β-gal activity than most other strains.

Lactobacillus casei Shirota, administered with Bifidobacterium breve Yakult for one month, produced significant and sustained improvement in symptom severity scores and hydrogen gas production in lactose-intolerant patients, with benefits persisting for 3 months after cessation. A meta-analysis combination trial also demonstrated reductions in LI symptoms.

Lactobacillus delbrueckii subsp. bulgaricus is a primary yogurt starter with EFSA-recognized β-galactosidase activity supporting the health claim for improved lactose digestion in lactose maldigestion. A 2023 meta-analysis identifies it as among the most effective probiotic strains for lactose intolerance due to highest β-gal activity. Included in the AJCN 2022 clinical trial as a reference strain.

Lactobacillus plantarum MP2026 produces endogenous β-galactosidase and was tested in a randomized placebo-controlled trial (n=44 LI subjects) in combination with Bifidobacterium animalis IM386, showing significant reduction in diarrhea and flatulence versus placebo. It uses lactose as a primary energy source even in the presence of glucose, making it a relevant functional strain for lactose intolerance.

Lactobacillus reuteri demonstrated significant improvement in abdominal pain, bloating, diarrhea, and flatulence in a randomized trial of 40 lactose-intolerant subjects at 8×10⁸ CFU/day for 10 days. A 2010 RCT (n=60) showed L. reuteri taken before dairy normalized lactose metabolization comparably to lactase supplementation. Meta-analytic evidence also supports its efficacy.

Lactobacillus rhamnosus HN001 combined with Bifidobacterium longum BB536 and vitamin B6 was evaluated in a randomized, double-blind, crossover study (n=23) of lactose-intolerant patients, demonstrating alleviation of persistent GI symptoms and favorable microbiome changes. Systematic reviews include L. rhamnosus among strains with demonstrated benefit in LI.

S. boulardii CNCM I-745 enhances intestinal lactase activity through polyamine-mediated upregulation of brush-border enzymes, providing a documented mechanistic basis for symptom relief in lactase-deficient individuals. This trophic effect on lactase is described in peer-reviewed mechanistic literature, though large dedicated clinical trials in lactose intolerant populations are lacking.

Streptococcus thermophilus is a classical yogurt bacterium that produces β-galactosidase, improving lactose digestion. EFSA approved a health claim for live yogurt cultures (including S. thermophilus) improving lactose digestion based on 14 human intervention studies. A 2023 meta-analysis identifies it as one of the most effective probiotic strains for LI due to highest β-gal activity. The New England Journal of Medicine published foundational evidence establishing its lactase activity.